COMPARISON OF ACELLULAR PERTUSSIS-VACCINE WITH WHOLE CELL VACCINE AS A BOOSTER IN CHILDREN 15 TO 18 MONTHS AND 4 TO 6 YEARS OF AGE

被引:41
作者
BERNSTEIN, DI [1 ]
SMITH, VE [1 ]
SCHIFF, GM [1 ]
RATHFON, HM [1 ]
BOSCIA, JA [1 ]
机构
[1] SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA
关键词
PERTUSSIS; VACCINE; ACELLULAR PERTUSSIS;
D O I
10.1097/00006454-199302000-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The safety and immunogenicity of a booster dose of a new acellular pertussis diphtheria-tetanus toxoids-pertussis vaccine (DTaP) were compared with whole cell pertussis component diphtheria-tetanus toxoids-pertussis vaccine (DTwP). Fifty children ages 15 to 18 months and 50 children ages 4 to 6 years were studied. The incidence of adverse reactions observed during the first 72 hours after vaccination in the DTaP/DTwP vaccinees were: pain, 32%/92% (P < 0.001); redness, 14%/24% (P = 0.2); swelling, 2%/14% (P < 0.03); fever. 52%/90% (P < 0.001); drowsiness, 14%/34% (P < 0.05); fussiness, 32%/88% (P < 0.001); and unusually poor appetite, 6%/42% (P < 0.001). The geometric mean titers of anti-pertussis toxin and anti-filamentous hemagglutinin antibody were also significantly (P < 0.001) higher in the DTaP compared to the DTwP recipients. When administered as a booster dose this DTaP vaccine, which has been chosen by the NIH for the second pertussis vaccine clinical efficacy trial, was more immunogenic for pertussis toxin and filamentous hemagglutinin and caused fewer and less severe adverse reactions compared with the Connaught DTwP vaccine used in this study.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 26 条
  • [1] CLINICAL AND SEROLOGIC RESPONSES TO ACELLULAR PERTUSSIS-VACCINE IN INFANTS AND YOUNG-CHILDREN
    ANDERSON, EL
    BELSHE, RB
    BARTRAM, J
    GURWITH, M
    HUNG, P
    LEVNER, M
    VERNON, SK
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1987, 141 (09): : 949 - 953
  • [2] DIFFERENCES IN REACTOGENICITY AND ANTIGENICITY OF ACELLULAR AND STANDARD PERTUSSIS VACCINES COMBINED WITH DIPHTHERIA AND TETANUS IN INFANTS
    ANDERSON, EL
    BELSHE, RB
    BARTRAM, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (04) : 731 - 737
  • [3] EFFICACY AND IMMUNOGENICITY OF ACELLULAR PERTUSSIS-VACCINE BY MANUFACTURER AND PATIENT AGE
    AOYAMA, T
    MURASE, Y
    KATO, M
    IWAI, H
    IWATA, T
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1989, 143 (06): : 655 - 659
  • [4] BIENNOW M, 1989, PEDIATRICS, V94, P62
  • [5] COMPARISON OF AN ACELLULAR PERTUSSIS-COMPONENT DIPHTHERIA-TETANUS-PERTUSSIS (DTP) VACCINE WITH A WHOLE-CELL PERTUSSIS-COMPONENT DTP VACCINE IN 17-MONTH-OLD TO 24-MONTH-OLD CHILDREN, WITH MEASUREMENT OF 69-KILODALTON OUTER-MEMBRANE PROTEIN ANTIBODY
    BLUMBERG, DA
    MINK, CM
    CHERRY, JD
    REISINGER, KS
    BLATTER, MM
    CONGENI, BL
    DEKKER, CL
    STOUT, MG
    MEZZATESTA, JR
    SCOTT, JV
    CHRISTENSON, PD
    [J]. JOURNAL OF PEDIATRICS, 1990, 117 (01) : 46 - 51
  • [6] CODY CL, 1981, PEDIATRICS, V68, P650
  • [7] DECKER M D, 1992, Pediatric Research, V31, p90A
  • [8] EDWARDS K M, 1992, Pediatric Research, V31, p91A
  • [9] DIPHTHERIA, TETANUS, AND PERTUSSIS-VACCINE - A COMPARISON OF THE IMMUNE-RESPONSE AND ADVERSE REACTIONS TO CONVENTIONAL AND ACELLULAR PERTUSSIS COMPONENTS
    EDWARDS, KM
    LAWRENCE, E
    WRIGHT, PF
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1986, 140 (09): : 867 - 871
  • [10] EDWARDS KM, 1991, PEDIATRICS, V88, P1019